European Clinical-Stage Cancer Vaccine Gains South Korean Support
PDC*line Pharma Raises A €20m Series B To fund NSCLC Phase I/II study
A group of Belgian and South Korean investors are providing series B funding to support an early-stage clinical study of an off-the-shelf cancer immunotherapy candidate based on an allogeneic plasmacytoid dendritic cell line.
